- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04088032
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
July 14, 2020 updated by: Alison Stopeck
A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer
The purpose of this study is to test the efficacy, safety and tolerability of a combination of immunotherapy and anticancer drugs presurgery in patients with hormone-receptor positive breast cancer.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The primary hypothesis is that a Programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor combined with a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor will be well tolerated in early stage, hormone receptor positive (HR+) breast cancer patients treated with neoadjuvant endocrine therapy (NET).
The secondary hypothesis and biomarker based endpoint is that patients with HR positive locally advanced breast cancer with low to intermediate stromal tumor-infiltrating lymphocytes (TILs) will demonstrate an increase in stromal TILs following NET when combined with abemaciclib and durvalumab for 4 cycles (16 weeks).
Study Type
Interventional
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- A signed, written informed consent will be obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
Postmenopausal women age ≥ 18 years at time of study entry. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women <50 years of age receiving luteinising hormone-releasing hormone (LHRH) agonist for ovarian suppression are also eligible for the study but must initiate LHRH agonist therapy at least 2 weeks prior to starting on study intervention.
- Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- Histologically confirmed estrogen and/or progesterone positive invasive breast cancer, defined as either estrogen and/or progesterone receptor (ER/PR) staining >10%, AND Human Epidermal Growth Factor Receptor 2 (HER2) negative by either Immunohistochemistry (IHC) or Fluorescent in situ Hybridization (FISH).
- Clinical stage II-III disease with no clinical or radiologic evidence of metastatic disease. Patients must have a measurable primary breast lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.
- Eastern Cooperative Oncology Group (ECOG) status < 1.
- Patient must be able to swallow pills.
Adequate organ and marrow function as defined below and in Table 1:
- Hemoglobin ≥ 9 g/deciliter
- Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 × institutional upper limit of normal (ULN)
- Bilirubin ≤ 1.5 × ULN; for subjects with documented/suspected Gilbert's disease, bilirubin ≤ 2 × ULN
- Creatinine clearance ≥ 50 mL/min as determined by the Cockcroft-Gault equation, or creatinine ≤1.5 x ULN
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Must have a life expectancy of at least 12 weeks.
Exclusion Criteria:
- Any serious preexisting medical condition(s) that would place the patient at increased risk for toxicities including interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel.
- Body weight < 30 kg (or 66.5 lbs.). If during the study, the patient's weight drops to < 30 Kg (or 66.5 lbs), they will be withdrawn from the study.
- Females who are pregnant or lactating.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, severe active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirement or compromise the ability of the subject to give written informed consent
- Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, Hashimoto's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are eligible
- History of significant cardiac disease including heart failure, ventricular arrhythmia, or prolonged QT syndrome.
- Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or a preexisting chronic condition resulting in baseline ≥ Grade 2 diarrhea.)
- History of primary immunodeficiency, or subjects who are known to be HIV (Human Immunodeficiency Virus ) positive
- History of organ transplant that requires use of immunosuppressives
- Known allergy or reaction to any of the study drugs.
- Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured
- Major surgical procedure (as defined by the investigator) within 30 days prior to the first dose of study drugs or still recovering from prior surgery
- Known history of tuberculosis
- Subjects who are known to be hepatitis B or C positive
- History of prior therapy with a checkpoint (PD-L1/PD-1) including durvalumab or CDK4/6 inhibitor
- History of prior ipsilateral radiation therapy to the cancer-affected breast
- History of prior therapy with an investigational anticancer therapy within 6 weeks prior to the first dose of study drugs
- Prior chemotherapy or aromatase inhibitor therapy for breast cancer
- Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal, topical, and inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
- Patients who must take strong cytochrome cytochrome P450 (CYP3A) inhibitors such as clarithromycin, diltiazem, verapamil, itraconazole, or ketoconazole
- Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
- Concurrent enrollment in another therapeutic clinical study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Active
Experimental treatment
|
Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: Through study completion, up to 24 weeks
|
The primary endpoints will be safety and tolerability of the study intervention
|
Through study completion, up to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic response at surgery
Time Frame: At the time of definitive surgery
|
Pathologic response at surgery by Preoperative Endocrine Prognostic Index (PEPI) score
|
At the time of definitive surgery
|
Pathologic response at surgery
Time Frame: At the time of definitive surgery
|
Pathologic response at surgery by change in Ki-67% from pre and surgical biopsies
|
At the time of definitive surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the number of T cells
Time Frame: At the time of definitive surgery
|
Change in subtype of T cell infiltrates and spatial relationship of T cells to tumor cells (number of T cells withing the tumor)
|
At the time of definitive surgery
|
Change in the number of T regs cells
Time Frame: At the time of definitive surgery
|
Change in number of T regs per tumor spatial unit
|
At the time of definitive surgery
|
Change in the number of macrophages
Time Frame: At the time of definitive surgery
|
Change in number of myeloid derived immunosuppressive cells (M1 vs M2 macrophages) per tumor spatial unit
|
At the time of definitive surgery
|
Changes in immune markers in the tumor specimens and/or peripheral blood
Time Frame: At the time of definitive surgery
|
Change in gene expression immune signatures (RNA quantification)
|
At the time of definitive surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Alison Stopeck, MD, Stony Brook University
- Principal Investigator: Lea Baer, MD, Stony Brook University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
October 1, 2019
Primary Completion (ANTICIPATED)
December 31, 2020
Study Completion (ANTICIPATED)
December 31, 2020
Study Registration Dates
First Submitted
September 10, 2019
First Submitted That Met QC Criteria
September 11, 2019
First Posted (ACTUAL)
September 12, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 16, 2020
Last Update Submitted That Met QC Criteria
July 14, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Site
- Breast Diseases
- Neoplasms
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Immunological
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Durvalumab
- Aromatase Inhibitors
Other Study ID Numbers
- 2019-00174 Neoadj Breast Pilot
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Breast Cancer
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Icahn School of Medicine at Mount SinaiTerminatedLocally Advanced Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedLocally Advanced Breast CancerBrazil
-
Spanish Breast Cancer Research GroupAstraZenecaRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerSpain
-
Imperial College LondonCancer Research UKCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerUnited Kingdom
-
Hospices Civils de LyonNot yet recruiting
-
RenJi HospitalRecruitingLocally Advanced Breast CancerChina
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Locally Advanced Breast CancerUnited States
Clinical Trials on Abemaciclib, durvalumab and aromatase inhibitor
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Mridula George, MDRecruiting
-
Eli Lilly and CompanyWithdrawnMetastatic Breast CancerUnited States, Taiwan, Italy, Austria, Germany, Puerto Rico, Belgium, Argentina, Brazil
-
PfizerCompletedMetastatic Breast CancerSpain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...RecruitingIntracranial Meningioma | Recurrent Meningioma | NF2 Gene MutationUnited States
-
Eli Lilly and CompanyCompletedBreast Neoplasms | Neoplasm MetastasisIndia
-
Dana-Farber Cancer InstituteEli Lilly and CompanyWithdrawnBreast Cancer
-
Institut für Klinische Krebsforschung IKF GmbH...Recruiting
-
Dana-Farber Cancer InstituteEli Lilly and CompanyActive, not recruiting
-
Dartmouth-Hitchcock Medical CenterActive, not recruiting